Anti-IL27 antibody - Aminoterminal end (ab62501)

Overview

  • Product nameAnti-IL27 antibody - Aminoterminal end
    See all IL27 primary antibodies
  • Description
    Rabbit polyclonal to IL27 - Aminoterminal end
  • SpecificityThis antibody reacts with IL27
  • Tested applicationsSuitable for: WB, ICC, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    A 16 amino acid synthetic peptide from near the amino terminus of human IL27 alpha subunit.

  • Positive control
    • EL4 cell lysate and EL4 cells

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab62501 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 2 - 4 µg/ml. Detects a band of approximately 39, 51 kDa (predicted molecular weight: 27 kDa).
ICC Use a concentration of 10 µg/ml.
ICC/IF Use at an assay dependent concentration.

Target

  • FunctionCytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL-27 subunit p28 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replivation.
  • Tissue specificityExpressed in monocytes and in placenta.
  • Sequence similaritiesBelongs to the IL-6 superfamily.
  • Post-translational
    modifications
    O-glycosylated.
  • Cellular localizationSecreted. Does not seem to be secreted without coexpression of EBI3.
  • Information by UniProt
  • Database links
  • Alternative names
    • EBI3 antibody
    • IL 27 antibody
    • IL 27 p28 subunit antibody
    • IL 27A antibody
    • IL 30 antibody
    • IL-27 subunit alpha antibody
    • IL-27-A antibody
    • IL27 antibody
    • IL27-A antibody
    • IL27A antibody
    • IL27A_HUMAN antibody
    • IL27p28 antibody
    • IL30 antibody
    • Interleukin 27 antibody
    • Interleukin 27 subunit alpha antibody
    • Interleukin 27, 28-KD subunit antibody
    • Interleukin 30 antibody
    • Interleukin-27 subunit alpha antibody
    • p28 antibody
    see all

Anti-IL27 antibody - Aminoterminal end images

  • Lane 1 : Anti-IL27 antibody - Aminoterminal end (ab62501) at 2 µg/ml
    Lane 2 : Anti-IL27 antibody - Aminoterminal end (ab62501) at 4 µg/ml

    Lane 1 : EL4 cell lysate
    Lane 2 : EL4 cell lysate

    Lysates/proteins at 15 µg per lane.

    Secondary
    Anti-rabbit IgG

    Predicted band size : 27 kDa
    Observed band size : 39,51 kDa (why is the actual band size different from the predicted?)
  • Immunocytochemistry of IL27 in EL4 cells with ab62501 antibody at 10 µg/ml.
  • Immunofluorescence analysis of Human dendritic cells, staining IL27 with ab62501.

    Cells were fixed with methanol, permeabilized with 0.1% Saponin and blocked with 4% BSA for 30 minutes at 25°C. Samples were incubated with primary antibody (10 µg/ml in blocking buffer) for 14 hours at 4°C. An AlexaFluor®488-conjugated goat anti-rabbit polyclonal IgG (1/100) was used as the secondary antibody.

    See Abreview

References for Anti-IL27 antibody - Aminoterminal end (ab62501)

ab62501 has not yet been referenced specifically in any publications.

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (dendritic cell)
Specification dendritic cell
Fixative Methanol
Permeabilization Yes - 0,1% Saponin / PBS
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 4% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Jan 02 2013

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (PBMCs)
Loading amount 15 µg
Specification PBMCs
Treatment see below
Gel Running Conditions Reduced Non-Denaturing (Native) (5-16% gel)
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Apr 04 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"